Compare VLRS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | ALVO |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Mexico | Luxembourg |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.4M | 1.0B |
| IPO Year | 2013 | 2021 |
| Metric | VLRS | ALVO |
|---|---|---|
| Price | $6.79 | $5.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $9.16 | $8.00 |
| AVG Volume (30 Days) | 437.1K | ★ 999.0K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.96 | $13.28 |
| Revenue Next Year | $12.62 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.79 | $2.94 |
| 52 Week High | $10.80 | $9.25 |
| Indicator | VLRS | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 74.12 |
| Support Level | $6.50 | $4.46 |
| Resistance Level | $8.03 | $5.44 |
| Average True Range (ATR) | 0.25 | 0.29 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 43.87 | 89.83 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.